2022 New Treatment Accelerator Grant - A/Prof Jason Lee

Project Summary

The Principal Investigator has identified a factor called “EHMT2” that makes cancer cells aggressive and is developing a novel drug to target it. The Project Team proposes to test the therapeutic efficacy of this novel drug in pancreatic cancer using several clinically-relevant models, and then further proposes to develop a test that can be used to identify patients most likely to benefit from this therapy. The Project team will also test whether this new drug is able to make other therapies that are used in the clinic work better. Based on studies on other cancer types such as breast cancer and melanoma, the Project Team anticipates that the new drug will reduce the growth of a pancreatic tumour and ultimately pave the way to a cure.